about
Study of the Chemotactic Response of Multicellular Spheroids in a Microfluidic DeviceSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migrationSynthesis of cryptolepine analogues as potential bioreducible anticancer agents.ERp29 is a ubiquitous resident of the endoplasmic reticulum with a distinct role in secretory protein production.Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation.Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treateQuantitative angiogenesis assays in vivo--a review.Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptorNon-invasive molecular imaging for preclinical cancer therapeutic development.RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.The Effect of Polysialic Acid Expression on Glioma Cell Nano-mechanics.Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells.Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.NCAM polysialylation during adherence transitions: live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7.Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.Use of the hollow fiber assay for the evaluation of DNA damaging agents.An agarose spot chemotaxis assay for chemokine receptor antagonists.Organometallic osmium arene complexes with potent cancer cell cytotoxicity.P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.Use of the hollow fibre assay for studies of tumor neovasculature.Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer.Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity.Guaianolide sesquiterpenes from Pulicaria crispa (Forssk.) Oliv.Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides.The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.Reducing the cost of screening novel agents using the hollow fibre assay.Heparin octasaccharides inhibit angiogenesis in vivo.Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine.Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model.
P50
Q27315499-2B652528-0314-44EA-A6B2-243BE8B22BFDQ27851612-E2FE3A04-A721-493A-8FE8-5AC44724CD27Q28535224-2F5D6662-0431-4825-92A3-358E4DDCE59DQ30832829-4B4C3EBA-D141-4A55-8418-4D7576C59F50Q34118888-20222BD3-6A0C-4287-856C-6D3373589AE8Q34458715-AAF02EFF-4CEE-4858-9B55-36964191A6ACQ35787553-E305D059-F638-4A1D-9E1A-7F672955D6FCQ35859765-4526066E-C62E-4429-885D-ED59E9C62228Q37513318-EA2DFA50-841B-454D-84A3-B057647A3243Q38089102-97240820-D8F5-4B18-870B-91B1A95981AFQ38161395-0C3DD506-0B52-4EA9-8A3B-D58039FD82E8Q38775866-026AB131-123E-4CEF-AF46-4EEBF38B42E8Q39011794-C4FA47C4-13F4-464F-B49D-639B430BF2E7Q39127374-A4947587-6B18-4B8B-B34A-25F373609202Q39146371-93A33581-5803-4C2A-9D68-4A74327C6F32Q39266629-B9C24061-D338-4CA0-BE4C-BD4228A4771FQ39491365-8FA3A6E5-6D24-4192-9E37-839F5E76A0F5Q39543143-88D8CB76-C931-415D-8AC8-5820C014DF7FQ39598216-1B90739B-EFF0-488C-950F-33ECAE979B87Q39639764-1915417F-A855-474D-B6F3-00EF287CDABEQ39705627-ED8E7F65-6FE4-46CD-B6E3-DABF80C4AAECQ39765512-CB1D9AB8-EBFF-4327-9B43-E94700CAC4F6Q39870429-4F758715-9BEA-4DA2-8411-B0A6069663AAQ39965751-675A47D4-FD52-4412-AD0C-484150DCD918Q39975613-165814C6-5A8A-4605-98DF-F647DD5CFCF5Q39986790-3E47596E-8FC6-4F72-8CF4-D324ACF17265Q40111212-551CD813-CE64-4C36-A276-B0848078EF1FQ40204735-BC7D96B4-4E48-444D-B862-2EB6F640A702Q40211295-0D36AA73-7AC4-4E37-BD8F-C45BE389578BQ40238058-5719430D-039B-464C-8FD8-86629BC835AEQ40257712-3C266008-2716-4350-90A9-1F4DB2F5EE01Q40349178-C87A4E9A-F2B3-4296-B44F-E0929737DEE4Q40374267-93D517A5-2B2A-4635-9D2A-712C5F4BB6F8Q40492295-2A32EEA8-312F-4822-B708-3228F7B01673Q40560364-FF597D65-F5F1-4188-B34F-BF34EE4A3BB7Q40587206-F9B35BE2-AB37-43B4-AB72-858C9CF5C6BEQ43828856-93738EE4-75C9-4995-BAB8-C9F6DC22ACE6Q43997494-91021AC2-7C36-4A70-842D-FD2B9C497535Q44487063-706CB846-5741-4800-BCF5-C1DB26594EA1Q44775387-19255D0A-3A48-4B4B-934D-34B378F4631C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Steven D Shnyder
@ast
Steven D Shnyder
@en
Steven D Shnyder
@es
Steven D Shnyder
@nl
Steven D Shnyder
@sl
type
label
Steven D Shnyder
@ast
Steven D Shnyder
@en
Steven D Shnyder
@es
Steven D Shnyder
@nl
Steven D Shnyder
@sl
altLabel
SD Shnyder
@en
Shnyder SD
@en
prefLabel
Steven D Shnyder
@ast
Steven D Shnyder
@en
Steven D Shnyder
@es
Steven D Shnyder
@nl
Steven D Shnyder
@sl
P106
P21
P31
P496
0000-0002-4647-2340